Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant ribociclib + aromatase inhibitor vs chemotherapy in HR+/HER2- early breast cancer
ChiCTR2500111780Phase 4Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ribociclib in breast cancer (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Preoperative endocrine prognostic index (PEPI). Started Nov 2025; status: recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500111780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111780.